trimetrexate has been researched along with Metastase in 9 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimetrexate, a nonclassical antifolate, was administered to 28 patients with progressive, metastatic breast cancer." | 7.67 | Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. ( Leiby, JM, 1988) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "Trimetrexate, a nonclassical antifolate, was administered to 28 patients with progressive, metastatic breast cancer." | 3.67 | Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. ( Leiby, JM, 1988) |
| "Trimetrexate (TMTX) is a second generation antifol with predominantly nonrenal elimination and antitumor activity superior to that of methotrexate in preclinical models." | 2.67 | Pharmacokinetic study of trimetrexate in combination with cisplatin. ( Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J, 1991) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| " The dosage chosen for the Phase 2 study, based only on the hematological dose limiting toxicity, was 10." | 1.27 | Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer. ( Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L, 1988) |
| " Dosage adjustment may have to be considered for patients who have renal dysfunction." | 1.27 | Clinical pharmacology of trimetrexate. ( Covington, WP; Ho, DH; Krakoff, IH; Legha, SS; Newman, RA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machiavelli, MR | 1 |
| Salum, G | 1 |
| Pérez, JE | 1 |
| Ortiz, EH | 1 |
| Romero, AO | 1 |
| Bologna, F | 1 |
| Vallejo, CT | 1 |
| Lacava, JA | 1 |
| Dominguez, ME | 1 |
| Leone, BA | 1 |
| Holen, KD | 1 |
| Saltz, LB | 1 |
| Hudes, GR | 2 |
| LaCreta, F | 1 |
| Walczak, J | 1 |
| Tinsley, P | 1 |
| Litwin, S | 1 |
| Comis, RL | 2 |
| O'Dwyer, PJ | 1 |
| Carlson, RW | 1 |
| Doroshow, JH | 1 |
| Odujinrin, OO | 1 |
| Flam, MS | 1 |
| Malec, M | 1 |
| Lamborn, KR | 1 |
| Mattson, K | 1 |
| Maasilta, P | 1 |
| Tammilehto, L | 1 |
| Holsti, LR | 1 |
| Grove, W | 1 |
| Ho, DH | 1 |
| Covington, WP | 1 |
| Legha, SS | 1 |
| Newman, RA | 1 |
| Krakoff, IH | 1 |
| Stewart, JA | 1 |
| Leiby, JM | 1 |
1 review available for trimetrexate and Metastase
| Article | Year |
|---|---|
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
3 trials available for trimetrexate and Metastase
| Article | Year |
|---|---|
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
Pharmacokinetic study of trimetrexate in combination with cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; F | 1991 |
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Evaluation; Drugs, Investigational; Female; Humans; Male | 1990 |
5 other studies available for trimetrexate and Metastase
| Article | Year |
|---|---|
Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cycloph | 1988 |
Clinical pharmacology of trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kinetics; Male; Metabolic Clear | 1987 |
Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Female; Humans; Male; Middle A | 1988 |
Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; | 1988 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |